Neostem Inc., of New York, randomized the first patient in the Intus phase III trial investigating the efficacy of the company's patient-specific targeted cancer immunotherapy candidate, NBS20 (eltrapuldencel-T), in patients with stage III recurrent or stage IV metastatic melanoma. Read More
Achaogen Inc., of South San Francisco, said it reached a settlement of its claim with the Defense Threat Reduction Agency (DTRA), a division of the U.S. Department of Defense, in which a $7.1 million settlement will be payable to Achaogen related to the company's 2007 contract with DTRA to develop novel antibacterials for the treatment of biodefense pathogens. Read More
Newron Pharmaceuticals SpA, of Milan, Italy, said it completed a capital increase, raising gross proceeds of CHF24.3 million (US$25.5 million) following the subscription by institutional investors of 843,072 newly issued shares. The fundraising was supported by current institutional shareholders and institutional investors from Europe and the U.S., including Aviva, J.P. Morgan Asset Management, Investor AB, Sphera Global Healthcare Fund and Nyenburgh. Read More
TOKYO – Two biotech companies from Japan are pooling complementary resources and products to tackle the rising incidence of dementia in a country with an aging population. Read More
"Casting a wide net" with its phase I trial testing MRX34, Mirna Therapeutics Inc. raked in $41.8 million by way of a series D financing that will enable a phase II experiment in the first half of next year, in a cancer indication yet to be decided upon, CEO Paul Lammers told BioWorld Today. Read More
First quarter sales in the bellwether diabetes franchise at Sanofi SA dropped 3.2 percent, to €1.837 billion (US$2.054 billion), the Paris-based pharma reported early Thursday. Read More
"Thank you, thank you, thank you, thank you." That's how NIH's deputy director for science, outreach and policy, Kathy Hudson, began to sum up her agency's gratitude for millions of dollars of new NIH funding called for in a new draft of the proposed 21st Century Cures Act discussed before a House subcommittee Thursday. Read More
Teva Pharmaceutical Industries Ltd., of Jerusalem, published a letter that Erez Vigodman, its president and CEO, sent to Robert J. Coury, executive chairman of the board of Mylan NV, of Potters Bar, UK, reiterating Teva's interest in acquiring Mylan. Read More
